Article Information
- Received October 26, 2011
- Revision received March 2, 2012
- Accepted March 4, 2012
- First published April 11, 2012.
- Version of record published April 11, 2012.
Author Information
Author contributions
Author contributions: A.I., J.V.R., and C.J.A. designed research; A.I. and J.V.R. performed research; A.I., J.V.R., and C.JA. analyzed data; A.I. and C.J.A. wrote the paper.
Disclosures
- Received October 26, 2011.
- Revision received March 2, 2012.
- Accepted March 4, 2012.
This work was supported by grants from the Biotechnology and Biological Sciences Research Council (BB/E0154761) and the Medical Research Council (G0601503). The research leading to these results has received funding from the European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013), ERC grant agreement number 243273. A.I. was supported by a Wellcome Trust Doctoral Fellowship; J.V.R was supported by a Rhodes Scholarship. We thank Marco Capogna, Karri Lamsa, and members of the Akerman lab for providing insightful comments and critically reading the manuscript.
- Correspondence should be addressed to Colin J. Akerman, Department of Pharmacology, Oxford University, Mansfield Road, Oxford OX1 3QT, UK. colin.akerman{at}pharm.ox.ac.uk
Online Impact